New hope for tough bone cancers: experimental combo enters human trials

NCT ID NCT04833582

Completed Disease control Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc Source: ClinicalTrials.gov ↗

Summary

This study tested the safety and effectiveness of a new drug called azenosertib (ZN-c3) when given with an existing chemotherapy drug, gemcitabine. It was for adults and teenagers (12+) whose osteosarcoma, a type of bone cancer, had returned or stopped responding to other treatments. The main goals were to find the right dose and see if the combination could help control the cancer.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Site 0103

Houston, Texas, 77030, United States
Site 0105

New York, New York, 10065, United States
Site 0106

Los Angeles, California, 90095, United States
Site 0107

Cincinnati, Ohio, 45229, United States
Site 0122

Seattle, Washington, 98195, United States
Site 0123

Portland, Oregon, 97239, United States
Site 0124

Oakland, California, 94609, United States
Site 0188

Richmond, Virginia, 23298, United States
Site 0193

Memphis, Tennessee, 38105, United States
Site 0195

Santa Monica, California, 90403, United States
Site 0197

Nashville, Tennessee, 37332, United States
Site 3601

Lyon, 69008, France
Site 3602

Marseille, 13385, France
Site 3604

Bordeaux, 33000, France
Site 3605

Toulouse, 31100, France
Site 3606

Paris, 75248, France
University of Florida College of Medicine

Gainesville, Florida, 32610, United States

Conditions

Explore the condition pages connected to this study.

OSTEOSARCOMA